About 1.5 million people died of tuberculosis (TB) in 2017, making it the most lethal infectious disease worldwide. A growing rise in drug-resistant TB is a major obstacle to successfully treating the illness.
Now, researchers at Washington University School of Medicine in St. Louis and Umea University in Sweden have found a compound that prevents and even reverses resistance to isoniazid, the most widely used antibiotic for treating tuberculosis.
The research, published the week of May 6 in Proceedings of the National Academy of Sciences, was conducted in bacteria growing in the lab, setting the stage for future studies in animals and people.
Using the compound in conjunction with isoniazid potentially could restore the antibiotic’s effectiveness in people with drug-resistant tuberculosis. The compound also may bolster the antibiotic’s power to kill TB bacteria – even those sensitive to drugs – which means doctors could start thinking about cutting down the onerous six-month treatment regimen they prescribe today.
“It is very hard for people to comply with such a long regimen,” said co-senior author Christina Stallings, PhD, an associate professor of molecular microbiology at the School of Medicine. “It’s four drugs. They have side effects. It’s no fun. The longer people have to be on antibiotics, the more issues with patient compliance you get, and that can lead to drug resistance and treatment failure. Here, we’ve found a compound that sensitizes bacteria to an antibiotic, prevents drug resistance from arising, and even reverses drug resistance – at least in the lab. If we can turn this compound into a drug for people, it could make our current therapies more effective and be really beneficial for fighting this pandemic.”
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. Once inside the body, the bacteria morph into a tougher form that can withstand more stress and is harder to kill. Rather than look for new and better antibiotics, Stallings and co-first authors Kelly Flentie, PhD, a former postdoctoral researcher at Washington University, and Gregory Harrison, a graduate student, decided to look for compounds that prevent the bacteria from toughening up. When put in a low-oxygen environment to mimic the stressful conditions TB bacteria encounter inside the body, the bacteria come together and form a thin film called a biofilm that is resilient to not only low-oxygen conditions but also to antibiotics and other stressors.
With the help of co-senior author Fredrik Almqvist, PhD, a professor of chemistry at Umea University, they screened 91 compounds that share a core chemical structure that inhibits biofilms in other bacterial species. The researchers found one compound, called C10, that did not kill the TB bacteria but prevented them from forming a biofilm.
Further experiments showed that blocking biofilm formation with C10 made the bacteria easier to kill with antibiotics and even curbed the development of antibiotic resistance. The researchers needed only a fraction of the amount of isoniazid to kill the TB bacteria when C10 was included than with isoniazid alone. In addition, one out of 1 million TB bacteria spontaneously become resistant to isoniazid when grown under typical laboratory conditions. But when the researchers grew TB bacteria with isoniazid and the compound, the drug-resistant mutant bacteria never arose.
“By combining C10, or something like it, with isoniazid we could enhance the potency of the antibiotic and block the TB bacteria from developing drug resistance,” Stallings said. “That means we might be able to shorten the treatment regimen.”
Most surprisingly, the compound even reversed drug resistance. TB bacteria with mutations in the gene katG can withstand isoniazid treatment. But such bacteria die when treated with isoniazid plus the compound, the researchers discovered. The bacteria had not lost their genetic resistance, but they’d lost the ability to survive when exposed to isoniazid, as long as it was given alongside C10.
“This was a totally unexpected finding,” Stallings said. “We had no idea we would be able to reverse drug resistance. But this could mean that with all those millions of isoniazid-resistant TB cases, if we use something like C10, we could give people the option of using isoniazid again.”
The compound is not ready to be used in people or even tested in animals, Stallings cautioned. This study was conducted on bacteria growing in a lab. The researchers are still figuring out whether the compound is safe and how it might be processed by the body.
“We have this great compound, and we’ve shown that it’s possible to prevent and reverse antibiotic resistance,” Stallings said. “But now we have to either improve on the compound itself so we can start testing it in animals, or figure out how it prevents biofilm formation so we can develop other drugs that target the pathway. We have a new strategy to treat TB, but it’s going to take time before it’s a reality.”
The Latest on: Drug-resistant TB
[google_news title=”” keyword=”drug-resistant TB” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug-resistant TB
- American Farms Have a Drug Problemon May 17, 2024 at 3:00 am
The growing risk from drug-resistant bacteria, fungi, viruses, and parasites, England’s former chief medical officer Sally Davies told The Guardian in an interview published this week, is “more acute” ...
- Aggressive contact tracing key to fight TB: Health officialon May 17, 2024 at 2:57 am
The Ministry of Health highlighted the need to step up contact investigation as part of the efforts to realize the target of eliminating tuberculosis (TB) by ...
- Experts developing immune-enhancing therapies to treat TB: Studyon May 16, 2024 at 8:24 pm
Experts are developing revolutionary immune-enhancing medicines known as host-directed therapies, which employ the body's immune system to target TB, to tackle even drug-resistant strains of the ...
- Opinion: UNGA should address TB and antimicrobial resistance togetheron May 15, 2024 at 8:33 am
Drug-resistant tuberculosis, which is spread through air and responsible for a large number of deaths, is part of antimicrobial resistance efforts. The United Nations General Assembly can pave the way ...
- Africa: MSF Reveals Cost of Landmark TB Clinical Trial in Push for Drug-Development Cost Transparencyon May 15, 2024 at 7:10 am
Press Release - At the fifth WHO Pharmaceutical Pricing and Reimbursement Policies conference today, Médecins Sans Frontières (MSF) presented the costs of its landmark TB-PRACTECAL clinical trial that ...
- ICMR releases Generic Concordance Study Protocol for assessing TB detection technologieson May 14, 2024 at 7:31 pm
ICMR releases Generic Concordance Study Protocol for assessing TB detection technologies: Shardul Nautiyal, Mumbai Wednesday, May 15, 2024, 08:00 Hrs [IST] The Indian Council of M ...
- Sketchy stem-cell treatments in Mexico led to drug-resistant infectionson May 13, 2024 at 2:26 pm
Three U.S. hospital patients contracted drug-resistant infections in Mexico in 2022 and were still being treated as of March 2024.
- What to know about TB after outbreak in Long Beach sickens 14on May 8, 2024 at 3:59 pm
A tuberculosis outbreak in Long Beach, California, has left 14 people sickened and one person dead. Here's everything you need to know about the illness.
- Public Health: 2 new drug-resistant TB cases on Guam, 3rd person being treated for relapseon May 5, 2024 at 10:55 pm
The Department of Public Health and Social Services has identified two new multidrug-resistant tuberculosis cases, while a third person on Guam is being treated for a relapse of the disease.
- Enhancing Immunity to Combat Tuberculosison April 27, 2024 at 2:30 pm
As estimated 410 000 cases and 160 000 deaths were due to multidrug-resistant TB (MDR-TB ... management and prevent spread of TB infections and drug resistance in this pivotal moment in ...
via Bing News